DNA Methylation:
Overcoming
Early Detection
Challenges in Cancer
We leveraged our 20 years of epigenomic expertise to help Universal Diagnostics (UDx) develop a customized early-detection workflow for colorectal cancer (CRC), integrating liquid biopsies with DNA methylation technologies for biomarker discovery and validation.
Capturing Biomarkers in Real-Time with Liquid Biopsy
Using cell-free DNA (cfDNA) isolated from plasma, biomarkers were monitored in realtime in the risk population.
DNA Methylation for Cancer Classification
Genome-wide methylation profiles from healthy and cancer patients were created to identify potential biomarker using our WGBS/EM-seq service.
Biomarker Validation
Once a pool of potential biomarkers was available, the best performers were identified and validated using our custom Targeted Methyl-seq service.
“With the help of Hologic Diagenode’s experts, we are developing blood tests that detect cancer in its earliest stages.”
Kristi Kruusmaa
Chief Scientific Officer
Universal Diagnostics